$IMRN

Immuron reported unaudited Q1 FY27 sales growth of 14% in Australia, a 19% decline in the U.S. due to timing, and a 286% increase in Canada. Management expects a positive outlook for the next quarter. According to the company, inventory in the U.S. has been replenished.

Immuron (IMC) released Phase 2 data for Travelan, showing safety and a 50% reduction in adverse events, but missed primary endpoints due to a low placebo attack rate. The company may need a larger study to create a significant catalyst.

Immuron (IMRN) shares rose 56% to $1.7350 after announcing a U.S. distribution deal for PROIBS with Calmino. PROIBS, a digestive health product, had a 94% helpfulness rate in a Calmino study. Immuron's stock volume reached 95.65 million shares, far above its average.

Immuron Ltd (IMRN) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 Immuron FY26 Preliminary Results Melbourne, Australia, August 28, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectations In February 2026 at the time the Company

Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported FY26 results exceeding expectations, with sales up 6% to A$7.7M and net profit up AUD$1.4M. Key milestones include FDA approval for IMM-529 and growth in Travelan® sales. The company plans to focus on North American expansion and partnering in FY27.

Immuron Limited (ASX: IMC, NASDAQ: IMRN) reported unaudited FY26 Travelan sales growth. Global FY26 sales were AUD 7.7 million, up 6% year over year, with 2H at AUD 3.5 million (+7%) and 4Q at AUD 2.0 million (+2%). Australia FY26 was AUD 5.8 million (+10%), while Canada fell to AUD 0.2 million (-55%) and the U.S. rose to AUD 1.8 million (+7%).

Immuron Limited (ASX: IMC; NASDAQ: IMRN) said it hired Pullan Consulting to help secure a strategic partner for IMM-529, its Phase 2 program to prevent or treat Clostridioides difficile infection. Immuron has FDA IND approval (IND 32095) and is running a randomized, double-blind placebo-controlled trial (up to 60 subjects). Lumanity estimates base-case yearly revenue of about $400M if successful.

Immuron (ASX:IMC) is strengthening its growth profile as its drug candidate IMM-529 progresses to Phase 2 clinical trials for recurrent Clostridioides difficile infection (CDI) after receiving FDA approval. The company is actively seeking a partner to advance IMM-529, which uses a differentiated three-target mechanism, while also reporting strong sales growth across its commercial gastrointestinal health products. This dual focus on pipeline development and commercial performance positions IMM-529 as a key value driver, targeting a significant market opportunity in CDI with sales up 16% in the recent quarter.

Immuron (ASX:IMC) reported continued sales growth in its key global markets for the first half, driven primarily by strong performance of its Travelan immune supplement in Australia and the United States. The company recorded overall sales of $4.2 million, a 5% increase, with significant gains from marketing efforts and new product launches, despite mixed results in Canada. Immuron aims to expand distribution and leverage its oral immunotherapy platform for future growth.

Immuron Ltd ADR (NASDAQ:IMRN) stock plunged 24.5% after a clinical trial for an ETEC hyperimmune bovine colostrum product failed to meet its primary endpoint. The company noted that the investigational product was not manufactured by Immuron and was administered differently than its commercial product, Travelan®, citing issues like participant non-compliance and improper administration. Despite the setback, Immuron plans to continue with FDA meetings and existing collaborations, while also advancing discussions for testing Travelan® against other E.coli strains.